Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial

https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00218-3/fulltext?dgcid=hubspot_update_feature_updatealerts_landia&utm_campaign=update-landia&utm_medium=email&_hsenc=p2ANqtz-8MNP8XFkBbZBOBJuxcax6eYcy9-qszGbBEZLU5Z2JbqDYxPHRMpDzhBG6-sJOgB2vZjBqdByfu1w3SASe_EtADR6UIrw&_hsmi=328193159&utm_content=328154919&utm_source=hs_email